These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 20220120)

  • 1. Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study.
    Nutt JG; Chung KA; Holford NH
    Neurology; 2010 Apr; 74(15):1191-7. PubMed ID: 20220120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study.
    Choudhury S; Pradhan R; Paul P; Das M; Gupta A; Ghosh P; Chatterjee S
    Neurol Res; 2014 Sep; 36(9):841-6. PubMed ID: 24601722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia.
    Stacy M; Galbreath A
    Clin Neuropharmacol; 2008; 31(1):51-6. PubMed ID: 18303491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial.
    Nutt JG; Carter JH; Carlson NE
    Arch Neurol; 2007 Mar; 64(3):319-23. PubMed ID: 17353373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiparkinsonian and anti-levodopa-induced dyskinesia effects obtained by stimulating the same site within the GPi in PD.
    Stanzione P; Mazzone P; Peppe A; Pierantozzi M; Stefani A; Bassi A; Bernardi G
    Neurology; 1998 Dec; 51(6):1776-7. PubMed ID: 9855559
    [No Abstract]   [Full Text] [Related]  

  • 6. The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia.
    Zhang YH; Tang BS; Song CY; Xu Q; Lou MX; Liu ZH; Yu RH; Yan XX; Guo JF
    Neurosci Lett; 2013 Nov; 556():109-12. PubMed ID: 24135335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors and predictors of levodopa-induced dyskinesia among multiethnic Malaysians with Parkinson's disease.
    Hashim HZ; Norlinah MI; Nafisah WY; Tan HJ; Raymond AA; Tamil AM
    Int J Neurosci; 2014 Mar; 124(3):187-91. PubMed ID: 23952588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacology of levodopa-induced dyskinesia.
    Nutt JG
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S160-4; discussion S164-6. PubMed ID: 10762144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prefrontal alterations in Parkinson's disease with levodopa-induced dyskinesia during fMRI motor task.
    Cerasa A; Pugliese P; Messina D; Morelli M; Gioia MC; Salsone M; Novellino F; Nicoletti G; Arabia G; Quattrone A
    Mov Disord; 2012 Mar; 27(3):364-71. PubMed ID: 22076870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of levodopa.
    Nutt JG
    Mov Disord; 2008; 23 Suppl 3():S580-4. PubMed ID: 18781675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of the response to levodopa during the first 4 years of therapy.
    Nutt JG; Carter JH; Lea ES; Sexton GJ
    Ann Neurol; 2002 Jun; 51(6):686-93. PubMed ID: 12112073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease.
    Nutt JG; Carter JH; Lea ES; Woodward WR
    Mov Disord; 1997 May; 12(3):285-92. PubMed ID: 9159720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pain fluctuations in Parkinson's disease].
    Yakovleva LA; Zalyalova ZA; Altunbaev RA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(9):41-44. PubMed ID: 26525814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Automated assessment of levodopa-induced dyskinesia: Evaluating the responsiveness of video-based features.
    Li MH; Mestre TA; Fox SH; Taati B
    Parkinsonism Relat Disord; 2018 Aug; 53():42-45. PubMed ID: 29748112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of Disabling Response Fluctuations and Dyskinesias for Dopamine Agonists Versus Levodopa in Parkinson's Disease.
    Haaxma CA; Horstink MW; Zijlmans JC; Lemmens WA; Bloem BR; Borm GF
    J Parkinsons Dis; 2015; 5(4):847-53. PubMed ID: 26444087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
    Warren Olanow C; Kieburtz K; Rascol O; Poewe W; Schapira AH; Emre M; Nissinen H; Leinonen M; Stocchi F;
    Mov Disord; 2013 Jul; 28(8):1064-71. PubMed ID: 23630119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990.
    Van Gerpen JA; Kumar N; Bower JH; Weigand S; Ahlskog JE
    Arch Neurol; 2006 Feb; 63(2):205-9. PubMed ID: 16476808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease.
    McColl CD; Reardon KA; Shiff M; Kempster PA
    Mov Disord; 2002 Nov; 17(6):1227-34. PubMed ID: 12465061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease].
    Jiménez-Jiménez FJ; Molina JA; Ortí-Pareja M
    Rev Neurol; 1999 May 1-15; 28(9):889-98. PubMed ID: 10390756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
    Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW
    Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.